MNMD News and Press, Mind Medicine (MindMed) Inc. From 05/28/24

2024-05-28 17:04:47 ET Gainers: Blue World Acquisition  ( BWAQ ) +57% . Insmed  ( INSM ) +33% . Vivid Seats  ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine  ( MNMD ) +7% . Losers: Inhib...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participa...

2024-05-23 12:15:00 ET Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi disc...

Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed ...

2024-05-10 11:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participa...

- GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life- -People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD- -Comprehensive Analyses of GAD Disease Burden in the US Conducted b...

2024-05-08 21:07:02 ET Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Conference Call May 08, 2024 04:30 PM ET Company Participants Robert Barrow - Chief Executive Officer Daniel Karlin - Chief Medical Officer Francois Lilienthal - Chief Commercial Officer ...

2024-05-08 16:42:28 ET More on Mind Medicine MindMed: Breakthrough Status From The FDA For LSD Therapy Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript MindM...

--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment-- --The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation t...